This multicenter, open-label exploratory trial of anti-endoglin inhibitor TRC105 (carotuximab), with and without VEGF inhibitor bevacizumab (ENDOT), demonstrated expected safety and tolerability in patients with glioblastoma that have progressed after chemoradiation and VEGF inhibitor therapy. Here, ENG is linked to glioblastoma.